dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUNIMEP
dc.date.accessioned2014-05-20T13:24:39Z
dc.date.available2014-05-20T13:24:39Z
dc.date.created2014-05-20T13:24:39Z
dc.date.issued2005-05-01
dc.identifierCurrent Drug Targets. Sharjah: Bentham Science Publ Ltd, v. 6, n. 3, p. 363-371, 2005.
dc.identifier1389-4501
dc.identifierhttp://hdl.handle.net/11449/7714
dc.identifier10.2174/1389450053765914
dc.identifierWOS:000228824900010
dc.identifier5361569184579557
dc.description.abstractTo achieve effective drug concentration at the intended site for a sufficient period of time is a requisite desired for many drug formulations. For drugs intended to ocular delivery, its poor bioavailability is due to pre-corneal factors. Most ocular diseases are treated by topical drug application in the form of solution, suspension and ointment. However, such dosage forms are no longer sufficient to combat some ocular diseases. Intravitreal drug injection is the current therapy for disorders in posterior segment. The procedure is associated with a high risk of complications, particularly when frequent, repeated injections are required. Thus, sustained-release technologies are being proposed, and the benefits of using colloidal carriers in intravitreal injections are currently under investigation for posterior drug delivery. This review will discuss recent progress and specific development issues relating to colloidal drug delivery systems, such as liposomes, niosomes, nanoparticles, and microemulsions in ocular drug delivery.
dc.languageeng
dc.publisherBentham Science Publ Ltd
dc.relationCurrent Drug Targets
dc.relation3.112
dc.relation0,906
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectophthalmic delivery
dc.subjectocular bioavailability
dc.subjectcolloidal drug delivery systems
dc.titleColloidal carriers for ophthalmic drug delivery
dc.typeOtros


Este ítem pertenece a la siguiente institución